Autoantibodies to ADAMTS13 in human immunodeficiency virus-associated thrombotic thrombocytopenic purpura

被引:0
|
作者
Meiring, Muriel [1 ,2 ]
Khemisi, Mmakgabu [1 ,2 ]
Louw, Susan [2 ,3 ]
Krishnan, Palanisamy [1 ]
机构
[1] Univ Free State, Fac Hlth Sci, Dept Haematol & Cell Biol, Bloemfontein, South Africa
[2] Univ Business Unit, Natl Hlth Lab Serv, Bloemfontein, South Africa
[3] Univ Witwatersrand, Dept Mol Med & Haematol, Johannesburg, South Africa
基金
新加坡国家研究基金会;
关键词
ADAMTS13; autoantibodies; HIV; thrombotic thrombocytopenic purpura; ANTI-ADAMTS13; ANTIBODIES; PLASMA-EXCHANGE; SPACER DOMAIN; HIV; INFECTION; IGG; INFUSION; CLEAVAGE; BINDING;
D O I
10.1111/vox.13738
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Thrombotic thrombocytopenic purpura (TTP) is a potentially fatal thrombotic microangiopathic disorder that can result from human immunodeficiency virus (HIV) infection. The pathogenesis involves a deficiency of the von Willebrand factor (vWF) cleaving protease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motifs member 13) and the presence of antiADAMTS13 autoantibodies. However, there is insufficient information regarding the epitope specificity and reactivity of these autoantibodies. This study aimed to perform epitope-mapping analysis to provide novel insights into the specific epitopes on ADAMTS13 domains affected by autoantibodies. Materials and Methods: The study analysed 59 frozen citrate plasma samples from HIV-associated TTP patients in South Africa, measuring ADAMTS13 activity using Technozyme (R) (R) ADAMTS13 activity test, total immunoglobulin (Ig) M and IgA antibodies levels using ELISA kit and purifying IgG antibodies using NAbTM Protein G spin columns. A synthetic ADAMTS13 peptide library was used for epitope mapping. Results: Overall, 90% of samples showed anti-ADAMTS13 IgG autoantibodies, with 64% of these antibodies being inhibitory, as revealed by mixing studies. Samples with ADAMTS13 antigen levels below 5% showed high anti-ADAMTS13 IgG autoantibody titres (>= 50 IU/mL), whereas those with 5%-10% levels had low autoantibody titres (<50 IU/mL).The metalloprotease, cysteine-rich and spacer domains were 100% involved in binding anti-ADAMTS13 IgG antibodies, with 58% of samples containing antibodies binding to the C-terminal part of the ADAMTS13 disintegrin-like domain, indicating different pathogenic mechanisms. Conclusion: The metalloprotease, cysteine-rich and spacer domains are the primary targets for anti-ADAMTS13 IgG autoantibodies in patients with HIV-associated TTP. These findings suggest potential effects on the proteolytic activity of ADAMTS13, highlighting the complex nature of the pathogenic mechanisms involved.
引用
收藏
页码:1285 / 1294
页数:10
相关论文
共 50 条
  • [21] Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura
    Cataland, Spero R.
    Wu, Haifeng M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (04) : 437 - 444
  • [22] ADAMTS13 autoantibodies, antigen and proteolytic activity in patients with thrombotic thrombocytopenic purpura.
    Shelat, SG
    Smith, P
    Ai, JH
    Long Zheng, X
    BLOOD, 2005, 106 (11) : 742A - 742A
  • [23] Familial acquired thrombotic thrombocytopenic purpura:: ADAMTS13 inhibitory autoantibodies in identical twins
    Studt, JD
    Hovinga, JAK
    Radonic, R
    Gasparovic, V
    Ivanovic, D
    Merkler, M
    Wirthmueller, U
    Dahinden, C
    Furlan, M
    Lämmle, B
    BLOOD, 2004, 103 (11) : 4195 - 4197
  • [24] Human immunodeficiency virus-associated thrombotic microangiopathies: Clinical characteristics and outcome according to ADAMTS13 activity
    Malak, S.
    Wolf, M.
    Millot, G. A.
    Mariotte, E.
    Veyradier, A.
    Meynard, J-L.
    Korach, J. -M.
    Malot, S.
    Bussel, A.
    Azoulay, E.
    Boulanger, E.
    Galicier, L.
    Devaux, E.
    Eschwege, V.
    Gallien, S.
    Adrie, C.
    Schlemmer, B.
    Rondeau, E.
    Coppo, P.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2008, 68 (03) : 337 - 344
  • [25] Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
    Jian, Cui
    Xiao, Juan
    Gong, Lingjie
    Skipwith, Christopher G.
    Jin, Sheng-Yu
    Kwaan, Hau C.
    Zheng, X. Long
    BLOOD, 2012, 119 (16) : 3836 - 3843
  • [26] ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies
    Tersteeg, Claudia
    Verhenne, Sebastien
    Roose, Elien
    Schelpe, An-Sofie
    Deckmyn, Hans
    De Meyer, Simon F.
    Vanhoorelbeke, Karen
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (02) : 209 - 221
  • [27] Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease
    Laemmle, Bernhard
    Hovinga, Johanna A. Kremer
    George, James N.
    HAEMATOLOGICA, 2008, 93 (02) : 172 - 177
  • [28] ADAMTS13 Deficiency and Thrombotic Thrombocytopenic Purpura Associated with Trimethoprim-Sulfamethoxazole
    Bapani, Sowjanya
    Epperla, Narendranath
    Kasirye, Yusuf
    Mercier, Richard
    Garcia-Montilla, Romel
    CLINICAL MEDICINE & RESEARCH, 2013, 11 (02) : 86 - 90
  • [29] Proteolysis of ADAMTS13 in acute phase thrombotic thrombocytopenic purpura
    Feys, H. B.
    Vandeputte, N.
    Peerlinck, K.
    Peyvandi, F.
    Vanhoorelbeke, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 655 - 655
  • [30] ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura
    Zheng, X. Long
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 211 - 225